Joint Book-Running Manager & Co-Manager: Repligen

July 19, 2019 – Repligen Corporation (NASDAQ: RGEN) (“Repligen”) announced the closing of its previously announced concurrent underwritten public offerings of an aggregate of 1.587 million shares of its common stock at a public offering price of $87.00 per share and $287.5 million aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (the "Offerings"), which includes the exercise in full of the underwriters’ option to purchase 207,000 additional Shares and $37.5 million additional Notes. Contemporaneously with the closing of the Offerings, Repligen used approximately $68.7 million and approximately 1.38 million shares of its common stock to settle a portion of its previously announced exchanges for approximately $68.5 million aggregate principal amount of its existing 2.125% Convertible Senior Notes due 2021. 

Janney Montgomery Scott LLC acted as a joint book-running manager on the common stock offering and a co-manager on the convertible notes offering.

About Repligen Corporation

Repligen Corporation is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Repligen’s corporate headquarters are in Waltham, MA (USA), with additional administrative and manufacturing operations in Marlborough, MA; Bridgewater, NJ; Rancho Dominguez, CA; Lund, Sweden; Breda, The Netherlands and Ravensburg, Germany.